| Cat. No. |
Product Name |
CAS No. |
Information |
| H9486 |
Ledaborbactam etzadroxil
|
1842399-68-1 |
VNRX-7145 is a novel, orally bioavailable, cyclic boronate-based β-lactamase inhibitor (BLI) that undergoes iotransformation to the active BLI VNRX-5236 in vivo; VNRX-5236 has potent and selective direct inhibitory activity against Ambler class A, C and D enzymes including those that hydrolyze carbapenems.The only clinically-available oral BLI, clavulanic acid (CLA), is active against some Class A extended spectrum β-lactamases (ESBLs) but has little to no activity against Class C cephalosporinases or carbapenem hydrolyzing enzymes (e.g., KPC and OXA-48) creating a need for new oral inhibitors with advanced spectrum. In this study, timekill kinetics were used to assess the ability of VNRX-5236 to rescue the bactericidal activity of ceftibuten against Enterobacteriaceae isolates expressing Class A, C, and D enzymes. |
| H9469 |
Fobrepodacin disodium
|
1384984-20-6 |
Fobrepodacin disodium (pVXc-486) is an orally active and potent phosphate prodrug of SPR719 (VXc-486). Fobrepodacin disodium has potent bactericidal activities in vivo. |
| H9468 |
Fobrepodacin
|
1384984-31-9 |
Fobrepodacin (pVXc-486) is an orally active and potent phosphate prodrug of SPR719 (VXc-486). Fobrepodacin has potent bactericidal activities in vivo. |
| H9380 |
OPC-167832
|
1883747-71-4 |
OPC-167832(Quabodepistat) is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis. |
| H9007 |
Pravibismane
|
175880-68-9 |
Pravibismane is the first in a new class of anti-infective drugs with broad-spectrum activity and a novel mechanism of action that halts microbial cellular metabolism with an MIC90 values of 0.5 μg/mL for all three organism groups;Pravibismane has an unprecedented ability to prevent and eradicate biofilms that contribute to chronic infection and facilitate antibiotic-resistance. |
| H8845 |
Ibezapolstat
|
1275582-97-2 |
Ibezapolstat is a novel agent effective against Clostridium difficile infection, synthetic purine that selectively inhibits the replication-specific DNA polymerase of Clostridium difficile; Ibezapolstat and its analogs strongly inhibited the growth of a wide variety of C. difficile strains. When administered orally in a hamster model of C. difficile-specific colitis,Ibezapolstat was as effective as oral vancomycin, the current agent of choice for treating severe forms of the human disease. |
| H8734 |
Alalevonadifloxacin
|
706809-20-3 |
Alalevonadifloxacin ,aslo known as WCK 2349, quinolone antibacterial. Alalevonadifloxacin is potentially useful to treat bacterial Gram-positive, Gram-negative and anaerobic infections; especially infections caused by resistant Gram-positive organism and Gram-negative organism, mycobacterial infections and emerging nosocomial pathogen infections. |
| H8687 |
Taniborbactam hydrochloride
|
2244235-49-0 |
Taniborbactam hydrochloride is a highly potent and specific beta-lactamase inhibitor, for use in combination with a licensed beta-lactam antibiotic |
| H1774 |
Mefloquine hydrochloride
|
51773-92-3 |
A quinoline antimalarial drug that is structurally related to the antiarrhythmic agent quinidine; inhibits autophagy and has been recognized as a potential target for cancer therapy. |
| H1393 |
PD 404182
|
72596-74-8 |
PD 404182 (PD404182, PD-404182) is a heterocyclic iminobenzothiazine derivative with antimicrobial and anti-inflammatory properties, a potent inhibitor of human DDAH1 activity (IC50=9 uM) and elevates cellular ADMA levels; significantly increases intracellular levels of ADMA and reduces LPS-induced NO production in cultured primary human vascular endothelial cells (ECs), abrogates the formation of tube-like structures by ECs in in vitro angiogenesis assay; also shows anti-HIV and anti-HSV activites. |
$ USD
Select Your Country or Region